3 completed, 1 active not recruiting, 1 recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow LDP-02: new trials by email Literature Review of LDP-02 trials Research Report on LDP-02
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2025-04-18 | 2026-06-29 |
| Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Infliximab, Vedolizumab - Colitis, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2020-07-09 | 2026-07-15 |
| Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease vedolizumab - Ulcerative Colitis, Crohn's Disease | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 72 | 2007-12-01 | 2014-07-18 |
| Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis Vedolizumab, Placebo - Ulcerative Colitis | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 47 | 2007-05-01 | 2014-07-18 |
| Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients LDP-02, Placebo - Crohn's Disease | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 185 | 2000-02-01 | 2008-04-09 |
Colitis, Ulcerative (2) · Crohn Disease (2) · Carcinoma, Non-Small-Cell Lung (1) · Colitis (1) · Graft vs Host Disease (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Urogenital Neoplasms (1)
Millennium Pharmaceuticals, Inc. (3) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1)
United States (2) · Canada (1)
Monzr M. Al Malki (1) · Yinghong Wang (1)
PMID 26893500, PMID 18829392, PMID 25996351
P30CA033572 (1)